Atrial Flutter: Management Overview

1. Acute/Hemodynamically Unstable Patients

• If flutter causes hypotension, pulmonary edema, ischemia, or severe symptoms: immediate synchronized electrical cardioversion (flutter typically responds to low energy, often 50-100 J).

2. Anticoagulation

• Use the CHA2DS2-VASc score plus bleeding risk assessment to guide anticoagulation, applying the same principles as atrial fibrillation.
• Anticoagulate before elective cardioversion (rhythm restoration) unless cardioversion is emergent for instability.
• Patients with atrial flutter carry roughly a 3% per year thromboembolic risk, so those at risk of recurrence need long-term anticoagulation similar to AF - Goldman-Cecil Medicine, p. 574; Harrison's Principles of Internal Medicine 22E.
• If CTI ablation is successful and flutter does not recur, long-term anticoagulation is generally not required.

3. Rate Control

• AV nodal-blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem/verapamil, or digoxin in select cases) are used, but rate control in atrial flutter is often harder to achieve than in AF because the organized atrial rhythm conducts less variably through the AV node.

4. Rhythm Control

• Antiarrhythmic drugs: sotalol, dofetilide, disopyramide, ibutilide, and amiodarone can be used for chemical cardioversion or maintenance of sinus rhythm, but more than 70% of patients relapse on drug therapy alone.
• Electrical cardioversion is effective for restoring sinus rhythm acutely.

5. Catheter Ablation - First-Line Therapy

• Radiofrequency ablation of the cavotricuspid isthmus is considered first-line therapy for typical (CTI-dependent) atrial flutter because of its high success rate (>95% cure rate), low complication risk, and low recurrence - Harrison's Principles of Internal Medicine, 22E, p. 1988; Goldman-Cecil Medicine, p. 574.
• Caveat: up to half of patients who undergo successful CTI ablation later develop atrial fibrillation, so surveillance continues after the procedure.
• Atypical atrial flutter (non-CTI-dependent, often left atrial, seen after mitral valve surgery or AF ablation) is also preferentially treated with catheter ablation, but success rates are lower; antiarrhythmic drugs or intermittent cardioversion are reasonable alternatives when ablation is less feasible.

Practical Stepwise Approach

1. Assess hemodynamic stability -> cardiovert immediately if unstable.
2. Stratify thromboembolic risk (CHA2DS2-VASc) -> start/continue anticoagulation.
3. Achieve rate control if remaining in flutter.
4. Decide on rhythm control strategy: cardioversion +/- antiarrhythmics, versus proceeding directly to catheter ablation (preferred long-term strategy for typical flutter given high cure rate).
5. Monitor for post-ablation atrial fibrillation; continue anticoagulation based on residual risk.

Note on evidence currency

Indications for Anticoagulation in Atrial Flutter

1. Risk-stratified long-term anticoagulation (chronic/non-cardioversion setting)

• Score 0 (men) / 1 (women, sex as the only risk factor): oral anticoagulation generally not recommended.
• Score 1 (men) / 2 (women): no anticoagulation, antiplatelet therapy, or an oral anticoagulant are all acceptable options - decision individualized.
• Score ≥2 (men) / ≥3 (women): oral anticoagulation is recommended - Tintinalli's Emergency Medicine, Table 18-13.

2. Peri-cardioversion anticoagulation (this is the indication most specific to flutter management)

• If flutter duration is unknown or ≥48 hours: anticoagulate with a direct oral anticoagulant (or heparin) for at least 3 weeks before elective cardioversion, OR obtain a transesophageal echocardiogram (TEE) to exclude atrial thrombus before proceeding sooner.
• If TEE shows thrombus, cardioversion is postponed and the patient is treated with therapeutic anticoagulation for at least 3 weeks before reattempting.
• All patients should be anticoagulated for at least 1 month after cardioversion if flutter/AF has been present ≥48 hours (or duration unknown), because atrial mechanical function ("atrial stunning") lags behind electrical recovery, keeping thromboembolic risk elevated even after sinus rhythm is restored - Goldman-Cecil Medicine; Fuster and Hurst's The Heart, 15th ed.
• Exception: if flutter onset is clearly and reliably <48 hours, cardioversion can often proceed without the 3-week pre-treatment, though many centers still anticoagulate periprocedurally, especially if any stroke risk factors are present.
• For hemodynamically unstable patients requiring emergency cardioversion, don't delay for anticoagulation - cardiovert first, then start anticoagulation as soon as possible afterward and continue for at least 4 weeks.

3. After catheter ablation

• If cavotricuspid isthmus ablation is successful and flutter does not recur, long-term anticoagulation is generally not necessary (assuming no other indication such as concomitant AF or an elevated CHA2DS2-VASc score from other risk factors).
• Anticoagulation decisions post-ablation remain somewhat debated, largely because of the substantial rate of subsequent atrial fibrillation in these patients, so ongoing risk factors still warrant reassessment - Harrison's Principles of Internal Medicine 22E, p. 1988.

4. Special note

Practical summary table

Evidence currency check